<table><tr><td>510(k) Owner:</td><td colspan="2">Alfa Wassermann Diagnostic Technologies, LLC 4 Henderson Drive West Caldwell, NJ 07006 Contact: Hyman Katz, Ph.D. Phone: 973-852-0158</td></tr><tr><td>Date Summary Prepared:</td><td>Fax: 973-852-0237 August 5, 2013</td><td></td></tr><tr><td>Device:</td><td>Trade Name: Classification: Common/Classification Name:</td><td>ACE γ-GT Reagent Class 1 Colorimetric Method, Gamma-Glutamyl Transpeptidase (21 C. F.R. § 862.1360)</td></tr><tr><td></td><td>Trade Name: Classification:</td><td>Product Code JPZ ACE Lipase Reagent Class 1</td></tr><tr><td></td><td>Common/Classification Name:</td><td>Lipase-Esterase, Enzymatic, Photometric, Lipase (21 C. F.R. § 862.1465)</td></tr><tr><td></td><td>Trade Name:</td><td>Product Code CHI ACE T4 Reagent</td></tr><tr><td></td><td>Classification: Common/Classification Name:</td><td>Class 2 Enzyme Immunoassay, Non-Radiolabeled, Total</td></tr><tr><td></td><td></td><td>Thyroxine (21 C. F.R. § 862.1700) Product Code KLI</td></tr><tr><td>Predicate Devices:</td><td>Manufacturer for reagent system predicates:</td><td></td></tr><tr><td>Device Descriptions: of the γ-glutamyl group from L-γ-glutamyl-3-carboxy-4-nitroanilide to glycylglycine in</td><td colspan="2">Alfa Wassermann ACE Clinical Chemistry System and ACE Reagents (K930104, K981377, K113253, K113382, K113438, K113437) In the ACE γ-GT Reagent assay, γ-GT in serum or heparin plasma catalyzes the transfer</td></tr><tr><td>thyroxine in the sample. The concentration of thyroxine is determined automatically by the ACE Clinical Chemistry Systems using a logarithmic calibration curve established with calibrators, which are provided separately.</td><td>In the ACE Lipase Reagent Assay, lipase in serum or heparin plasma acts on a natural substrate, 1,2-diglyceride, to liberate 2-monoglyceride. This is hydrolyzed by monoglyceride lipase (a highly specific enzyme for monoglyceride) into glycerol and free fatty acid. Glycerol kinase acts on glycerol to form glycerol-3-phosphate, which is in turn acted on by glycerol-3-phosphate oxidase to generate hydrogen peroxide. Peroxidase converts the hydrogen peroxide, 4-Aminoantipyrine and TOOS (N-ethyl-N- (2-hydroxy-3-sulfopropyl)-m-toluidine) into a quinine dye. The rate of formation of the dye, determined bichromatically at an absorbance of 573 nm/692 nm, is proportional to the lipase activity in the sample. The ACE T4 Assay is a homogeneous enzyme immunoassay using ready-to-use liquid ACE T4 Reagent. The assay uses 8-anilino-1-naphthalene sulfonic acid (ANS) to dissociate thyroxine from the plasma binding proteins. Using specific antibodies to thyroxine, this assay is based on the competition of glucose-6-phosphate dehydrogenase (G6PD) labeled thyroxine and the dissociated thyroxine in the sample for a fixed amount of specific antibody binding sites. In the absence of thyroxine from the sample, the thyroxine labeled G6PD in the second reagent is bound by the specific antibody in the first reagent, inhibiting the enzyme's activity. The enzyme G6PD catalyzes the oxidation of glucose-6-phosphate (G6P) with nicotinamide adenine dinucleotide (NAD*) to form 6-phosphogluconate and reduced nicotinamide adenine dinucleotide (NADH). NADH strongly absorbs at 340 nm whereas NAD+ does not. The rate of conversion, determined by measuring the increase in absorbance bichromatically at 340 nm/505 nm during a fixed time interval, is directly proportional to the amount of</td></tr><tr><td>Intended Use: The ACE Lipase Reagent is intended for the quantitative determination of lipase activity in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Lipase measurements are used in diagnosis and treatment of diseases of the pancreas such as acute pancreatitis and obstruction of the pancreatic duct. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only. The ACE T4 Reagent is intended for the quantitative determination of total thyroxine</td><td>Indications for Use: The ACE γ-GT Reagent is intended for the quantitative determination of gamma- glutamyltransferase activity in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Gamma-glutamyltransferase measurements are used in the diagnosis and treatment of liver diseases such as alcoholic cirrhosis and primary and secondary liver tumors. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only.</td></tr><tr><td>Technological Characteristics: and buffer.</td><td>(T4) in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Total thyroxine measurements are used in the diagnosis and treatment of thyroid diseases. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only. The ACE γ-GT Reagent consists of two reagent bottles (γ-GT Buffer and γ-GT Substrate). The reagent contains L-γ-glutamyl-3-carboxy-4-nitroanilide, glycylglycine The ACE Lipase Reagent is composed of two reagent bottles (Lipase Reagent and</td></tr><tr><td></td><td>Lipase Activator). The Lipase Reagent (R1) contains: 1,2-diglyceride, monoglyceride lipase, glycerol kinase, glycerol-3-phosphate oxidase, N-ethyl-N-(2-hydroxy-3- sulfopropyl)-m-toluidine, ATP, peroxidase, colipase, human serum albumin, ascorbate oxidase, cholic acid and buffer. The Lipase Activator contains: deoxycholate, 4- aminoantipyrene and buffer. The ACE T4 Reagent is composed of two reagent bottles (Antibody/Substrate Reagent and Enzyme Conjugate Reagent). The Antibody/Substrate Reagent (R1) contains: mouse monoclonal anti-thyroxine antibody, 8-anilino-1-naphthalene sulfonic acid, glucose-6-phosphate, nicotinamide adenine dinucleotide and Tris buffer. The Enzyme Conjugate Reagent (R2) contains: glucose-6-phosphate dehydrogenase labeled with thyroxine and Tris buffer.</td></tr></table>

Device Comparison with Predicate   
ACE $\gamma$ -GT Reagent   

<table><tr><td colspan="1" rowspan="1">γ-GT</td><td colspan="1" rowspan="1">Candidate Device</td><td colspan="1" rowspan="1">Predicate Devicek930104(ACE y-GT Reagent)</td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indications forUse</td><td colspan="1" rowspan="1">The ACE γ-GT Reagent is intended forthe quantitative determination of gamma-glutamyltransferase activity.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Platforms</td><td colspan="1" rowspan="1">ACE, ACE Alera® and ACE AxcelClinical Chemistry Systems</td><td colspan="1" rowspan="1">ACE Clinical ChemistrySystem</td></tr><tr><td colspan="1" rowspan="1">Method</td><td colspan="1" rowspan="1">Photometric</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibration Stability</td><td colspan="1" rowspan="1">Not a calibrated test</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">On Board Stability</td><td colspan="1" rowspan="1">30 days</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Serum and lithium heparin plasma</td><td colspan="1" rowspan="1">Serum</td></tr><tr><td colspan="1" rowspan="1">Sample Volume</td><td colspan="1" rowspan="1">5μL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reaction Volume</td><td colspan="1" rowspan="1">170 μL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Expected values</td><td colspan="1" rowspan="1">Male: 13-68 U/LFemale: 11-48 U/L</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measuring range</td><td colspan="1" rowspan="1">7-950 U/L</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Stability</td><td colspan="1" rowspan="1">Separated from cells, gamma-glutamyltransferase is stable 7 days at4-8°C and up to 1 year at -20°C.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">ACE Lipase Reagent</td></tr><tr><td colspan="1" rowspan="1">Lipase</td><td colspan="1" rowspan="1">Candidate Device</td><td colspan="1" rowspan="1">Predicate Devicek930104(ACE Lipase Reagent)</td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indications forUse</td><td colspan="1" rowspan="1">The ACE Lipase Reagent is intended forthe quantitative determination of lipaseactivity.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Platforms</td><td colspan="1" rowspan="1">ACE, ACE Alera® and ACE AxcelClinical Chemistry Systems</td><td colspan="1" rowspan="1">ACE Clinical ChemistrySystem</td></tr><tr><td colspan="1" rowspan="1">Method</td><td colspan="1" rowspan="1">Photometric</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibration Stability</td><td colspan="1" rowspan="1">20 days</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">On Board Stability</td><td colspan="1" rowspan="1">20 days</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Serum and lithium heparin plasma</td><td colspan="1" rowspan="1">Serum</td></tr><tr><td colspan="1" rowspan="1">Sample Volume</td><td colspan="1" rowspan="1">3μL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reaction Volume</td><td colspan="1" rowspan="1">263 μL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Expected values</td><td colspan="1" rowspan="1">&lt;60 U/L</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measuring range</td><td colspan="1" rowspan="1">15-700 U/L</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Stability</td><td colspan="1" rowspan="1">Stable for 7 days at 20-25°C, three weeksat 4-8°C and at -20°C for one year.</td><td colspan="1" rowspan="1">Same</td></tr></table>

![](images/757000f7092b5a5f6e0be147a4ce6aac5438aba890dd9fd52e2c9dc6ef3537f7.jpg)

<table><tr><td rowspan=1 colspan=3>ACE T4 Reagent</td></tr><tr><td rowspan=1 colspan=1>T4</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate Devicek981377(ACE T4 Reagent)</td></tr><tr><td rowspan=1 colspan=1>IntendedUse/Indicationsfor Use</td><td rowspan=1 colspan=1>ACE T4 Reagent is intended forthe quantitative determination oftotal thyroxine (T4).</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Platforms</td><td rowspan=1 colspan=1>ACE, ACE Alera® and ACE AxcelClinical Chemistry Systems</td><td rowspan=1 colspan=1>ACE Clinical ChemistrySystem</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Photometric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Stability</td><td rowspan=1 colspan=1>5 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On Board Stability</td><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum and lithium heparin plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>5μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reaction Volume</td><td rowspan=1 colspan=1>315 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected values</td><td rowspan=1 colspan=1>5.0 - 12.0 μg/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measuring range</td><td rowspan=1 colspan=1>1.3-19.6 μg/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Stability</td><td rowspan=1 colspan=1>Specimen stable for 7 days at 4-8°Cand 1 month at -20°C.</td><td rowspan=1 colspan=1>Same</td></tr></table>

Performance

Data:

# Performance data for the Alfa Wassermann ACE Reagents run on the Alfa Wassermann ACE, ACE Alera and ACE Axcel Clinical Chemistry Systems

In-House Precision: Serum vs. Plasma - ACE y-GT Reagent   

<table><tr><td rowspan=1 colspan=10>Precision (SD, %CV)</td></tr><tr><td rowspan=2 colspan=1>γ-GTU/L</td><td rowspan=1 colspan=3>*  ACE</td><td rowspan=1 colspan=3>ACE Alera</td><td rowspan=1 colspan=3>ACE Axcel</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>:Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Serum Low</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>0.9,2.4%</td><td rowspan=1 colspan=1>1.2,3.1%</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>0.9,2.4%</td><td rowspan=1 colspan=1>1.0,2.5%</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>0.71.8%</td><td rowspan=1 colspan=1>0.9,2.3%</td></tr><tr><td rowspan=1 colspan=1>Plasma Low</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>0.4, 1.0%</td><td rowspan=1 colspan=1>0.8, 2.2%</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0.7, 1.9%</td><td rowspan=1 colspan=1>0.7, 1.9%</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>0.7, 2.0%</td><td rowspan=1 colspan=1>0.9,2.4%</td></tr><tr><td rowspan=1 colspan=1>Serum Mid</td><td rowspan=1 colspan=1>313</td><td rowspan=1 colspan=1>2.4,0.8%</td><td rowspan=1 colspan=1>2.8,0.9%</td><td rowspan=1 colspan=1>314</td><td rowspan=1 colspan=1>3.9, 1.3%</td><td rowspan=1 colspan=1>4.5,1.4%</td><td rowspan=1 colspan=1>318</td><td rowspan=1 colspan=1>2.0, 0.6%</td><td rowspan=1 colspan=1>2.6,0.8%</td></tr><tr><td rowspan=1 colspan=1>Plasma Mid</td><td rowspan=1 colspan=1>316</td><td rowspan=1 colspan=1>2.4,0.8%</td><td rowspan=1 colspan=1>3.0,0.9%</td><td rowspan=1 colspan=1>317</td><td rowspan=1 colspan=1>·1.7,0.5%</td><td rowspan=1 colspan=1>2.4,0.8%</td><td rowspan=1 colspan=1>319</td><td rowspan=1 colspan=1>2.6,0.8%</td><td rowspan=1 colspan=1>2.9, 0.9%</td></tr><tr><td rowspan=1 colspan=1>Serum High</td><td rowspan=1 colspan=1>602</td><td rowspan=1 colspan=1>2.3,0.4%</td><td rowspan=1 colspan=1>2.6, 0.4%</td><td rowspan=1 colspan=1>601</td><td rowspan=1 colspan=1>4.2,0.7%</td><td rowspan=1 colspan=1>6.1, 1.0%</td><td rowspan=1 colspan=1>606</td><td rowspan=1 colspan=1>4.2. 0.7%</td><td rowspan=1 colspan=1>5.4.0.9%</td></tr><tr><td rowspan=1 colspan=1>Plasma High</td><td rowspan=1 colspan=1>605</td><td rowspan=1 colspan=1>3.6, 0.6%</td><td rowspan=1 colspan=1>4.4, 0.7%</td><td rowspan=1 colspan=1>604</td><td rowspan=1 colspan=1>4.3,0.7%</td><td rowspan=1 colspan=1>4.9, 0.8%</td><td rowspan=1 colspan=1>608</td><td rowspan=1 colspan=1>4.4, 0.7%</td><td rowspan=1 colspan=1>5.9, 1.0%</td></tr></table>

In-House Precision Serum vs. Plasma

In-House Precision: Serum vs. Plasma - ACE Lipase Reagent   

<table><tr><td rowspan=1 colspan=10>Precision (SD, %CV)                ...   ...  </td></tr><tr><td rowspan=2 colspan=1>LipaseU/L</td><td rowspan=1 colspan=3>ACE</td><td rowspan=1 colspan=3>ACE Alera</td><td rowspan=1 colspan=3>ACE Axcel</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total::</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Serum Low</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>1.7,3.6%</td><td rowspan=1 colspan=1>3.2, 6.7%</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>1.6,3.5%</td><td rowspan=1 colspan=1>2.9,6.4%</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>2.8.6.3%</td><td rowspan=1 colspan=1>3.0.6.9%</td></tr><tr><td rowspan=1 colspan=1>Plasma Low</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>2.2, 4.6%</td><td rowspan=1 colspan=1>3.2,6.6%</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>1.5,3.2%</td><td rowspan=1 colspan=1>3.5.7.4%</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>2.6,5.5%</td><td rowspan=1 colspan=1>3.1,6.4%</td></tr><tr><td rowspan=1 colspan=1>Serum Mid</td><td rowspan=1 colspan=1>283</td><td rowspan=1 colspan=1>5.1,1.8%</td><td rowspan=1 colspan=1>13.1, 4.6%</td><td rowspan=1 colspan=1>286</td><td rowspan=1 colspan=1>3.8, 1.3%</td><td rowspan=1 colspan=1>19.1, 6.7%</td><td rowspan=1 colspan=1>280</td><td rowspan=1 colspan=1>3.3, 1.2%</td><td rowspan=1 colspan=1>4.0, 1.4%</td></tr><tr><td rowspan=1 colspan=1>Plasma Mid</td><td rowspan=1 colspan=1>278</td><td rowspan=1 colspan=1>2.6.0.9%</td><td rowspan=1 colspan=1>11.5.4.1%</td><td rowspan=1 colspan=1>278</td><td rowspan=1 colspan=1>2.2.0.8%</td><td rowspan=1 colspan=1>20.0. 7.2%</td><td rowspan=1 colspan=1>272</td><td rowspan=1 colspan=1>4.8, 1.8%</td><td rowspan=1 colspan=1>6.8, 2.5%</td></tr><tr><td rowspan=1 colspan=1>Serum High</td><td rowspan=1 colspan=1>545</td><td rowspan=1 colspan=1>3.9,0.7%</td><td rowspan=1 colspan=1>24.3, 4.5%</td><td rowspan=1 colspan=1>547</td><td rowspan=1 colspan=1>4.3, 0.8%</td><td rowspan=1 colspan=1>37.5,6.9%</td><td rowspan=1 colspan=1>534</td><td rowspan=1 colspan=1>5.5.1.0%</td><td rowspan=1 colspan=1>9.5, 1.8%</td></tr><tr><td rowspan=1 colspan=1>Plasma High</td><td rowspan=1 colspan=1>524</td><td rowspan=1 colspan=1>5.9, 1.1%</td><td rowspan=1 colspan=1>18.9, 3.6%</td><td rowspan=1 colspan=1>528</td><td rowspan=1 colspan=1>5.0, 1.0%</td><td rowspan=1 colspan=1>31.7,6.0%</td><td rowspan=1 colspan=1>518</td><td rowspan=1 colspan=1>5.8, 1.1%</td><td rowspan=1 colspan=1>10.2,2.0%</td></tr></table>

In-House Precision: Serum vs. Plasma - ACE T4 Reagent   

<table><tr><td rowspan=1 colspan=10>Precision (SD, %CV)                             ::</td></tr><tr><td rowspan=2 colspan=1>T4μg/dL</td><td rowspan=1 colspan=3>ACE</td><td rowspan=1 colspan=3>ACE Alera</td><td rowspan=1 colspan=3>ACE Axcel</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Serum Low</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>0.17,2.2%</td><td rowspan=1 colspan=1>0.35, 4.5%</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>0.15,2.0%</td><td rowspan=1 colspan=1>0.19,2.4%</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>0.18, 2.3%</td><td rowspan=1 colspan=1>0.21, 2.6%</td></tr><tr><td rowspan=1 colspan=1>Plasma Low</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>0.28, 3.5%</td><td rowspan=1 colspan=1>0.29,3.8%</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>0.14, 1.9%</td><td rowspan=1 colspan=1>0.21, 2.7%</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>0.15, 1.9%</td><td rowspan=1 colspan=1>0.21,2.7%</td></tr><tr><td rowspan=1 colspan=1>Serum Mid</td><td rowspan=1 colspan=1>12.7</td><td rowspan=1 colspan=1>0.46, 3.6%</td><td rowspan=1 colspan=1>0.63, 4.9%</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>0.24, 1.9%</td><td rowspan=1 colspan=1>0.48, 3.9%</td><td rowspan=1 colspan=1>12.9</td><td rowspan=1 colspan=1>0.30,2.3%</td><td rowspan=1 colspan=1>0.43, 3.4%</td></tr><tr><td rowspan=1 colspan=1>Plasma Mid</td><td rowspan=1 colspan=1>13.1</td><td rowspan=1 colspan=1>0.24, 1.8%</td><td rowspan=1 colspan=1>0.50,3.8%</td><td rowspan=1 colspan=1>12.9</td><td rowspan=1 colspan=1>0.28.2.2%</td><td rowspan=1 colspan=1>0.67,5.2%</td><td rowspan=1 colspan=1>13.2</td><td rowspan=1 colspan=1>0.19.1.5%</td><td rowspan=1 colspan=1>0.71,5.4%</td></tr><tr><td rowspan=1 colspan=1>Serum High</td><td rowspan=1 colspan=1>17.3</td><td rowspan=1 colspan=1>0.50, 2.9%</td><td rowspan=1 colspan=1>0.74,4.3%</td><td rowspan=1 colspan=1>17.1</td><td rowspan=1 colspan=1>0.27, 1.6%</td><td rowspan=1 colspan=1>0.57, 3.3%</td><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>0.50, 2.9%</td><td rowspan=1 colspan=1>0.75,4.3%</td></tr><tr><td rowspan=1 colspan=1>Ptasma High</td><td rowspan=1 colspan=1>17.6</td><td rowspan=1 colspan=1>0.76, 4.3%</td><td rowspan=1 colspan=1>0.76,4.3%</td><td rowspan=1 colspan=1>17.4</td><td rowspan=1 colspan=1>0.41, 2.4%</td><td rowspan=1 colspan=1>0.44,2.6%</td><td rowspan=1 colspan=1>17.6</td><td rowspan=1 colspan=1>0.60, 3.4%</td><td rowspan=1 colspan=1>0.60, 3.4%</td></tr></table>

Data:

In-House   
Matrix   
Comparison Serum vs.   
Plasma

# Performance data for the Alfa Wassermann ACE Reagents run on the Alfa Wassermann ACE, ACE Alera and ACE Axcel Clinical Chemistry Systems

In-House Matrix Comparison: Serum vs. Plasma - ACE y-GT Reagent   

<table><tr><td rowspan=1 colspan=1>System</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>Results - Serum vs. Plasma</td></tr><tr><td rowspan=1 colspan=1>ACE100 pairs</td><td rowspan=1 colspan=1>9 - 886 U/L</td><td rowspan=1 colspan=1>Slope: 0.972Intercept: 1.5Correlation: 0.9990Std. Error Est: 7.9Confidence Interval Slope: 0.964 to 0.981Confidence Interval Intercept: -0.3 to 3.3</td></tr><tr><td rowspan=1 colspan=1>ACE Alera97 pairs</td><td rowspan=1 colspan=1>9 - 841 U/L</td><td rowspan=1 colspan=1>Slope: 0.960Intercept: 2.8Correlation: 0.9989Std. Error Est: 8.2Confidence Interval Slope: 0.951 to 0.969Confidence Interval Intercept: 0.8 to 4.7</td></tr><tr><td rowspan=1 colspan=1>ACE Axcel53 pairs</td><td rowspan=1 colspan=1>10 - 910 U/L</td><td rowspan=1 colspan=1>Slope: 0.987Intercept: 4.0Correlation: 0.9973Std. Error Est: 16.5Confidence Interval Slope: 0.967 to 1.008Confidence Interval Intercept: -1.8 to 9.8</td></tr></table>

In-House Matrix Comparison: Serum vs. Plasma - ACE Lipase Reagent   

<table><tr><td rowspan=1 colspan=1>System</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>Results - Serum vs. Plasma</td></tr><tr><td rowspan=1 colspan=1>ACE42 pairs</td><td rowspan=1 colspan=1>16 - 642 U/L</td><td rowspan=1 colspan=1>Slope: 1.024Intercept: -2.5Correlation: 0.9992Std. Error Est: 6.4Confidence Interval Slope: 1.01 1 to 1.038Confidence Interval Intercept: -5.0 to -0.1</td></tr><tr><td rowspan=1 colspan=1>ACE Alera43 pairs</td><td rowspan=1 colspan=1>19 - 640 U/L</td><td rowspan=1 colspan=1>Slope: 1.022Intercept: -0.9Correlation: 0.9994Std. Error Est: 5.5Confidence lnterval Slope: 1.010 to 1.033Confidence Interval Intercept: -3.0 to 1.2</td></tr><tr><td rowspan=1 colspan=1>ACE Axcel62 pairs</td><td rowspan=1 colspan=1>15 - 627 U/L</td><td rowspan=1 colspan=1>Slope: 0.980Intercept: -2.0Correlation: 0.9947Std. Error Est: 13.2Confidence Interval Slope: 0.954 to 1.007Confidence Interval Intercept: -5.9 to 2.0</td></tr></table>

![](images/621c48ecfff3cfb7a998651d99be929820e3c1bdc826f38240cbeb6863b66895.jpg)

In-House Matrix Comparison: Serum vs. Plasma - ACE T4 Reagent   

<table><tr><td rowspan=1 colspan=1>System</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>Results - Serum vs. Plasma</td></tr><tr><td rowspan=1 colspan=1>ACE55 pairs</td><td rowspan=1 colspan=1>2.0 - 19.3 µg/dL</td><td rowspan=1 colspan=1>Slope: 0.963Intercept: 0.35Correlation: 0.9847Std. Error Est: 0.54Confidence Interval Slope: 0.916 to 1.009Confidence Interval Intercept: -0.03 to 0.73</td></tr><tr><td rowspan=1 colspan=1>ACE Alera55 pairs</td><td rowspan=1 colspan=1>1.9 - 18.6 μg/dL</td><td rowspan=1 colspan=1>Slope: 0.976Intercept: 0.17Correlation: 0.9870Std. Error Est: 0.49Confidence Interval Slope: 0.933 to 1.019Confidence Interval Intercept: -0.18 to 0.51</td></tr><tr><td rowspan=1 colspan=1>ACE Axcel55 pairs</td><td rowspan=1 colspan=1>2.1 - 17.6 µg/dL</td><td rowspan=1 colspan=1>Slope: 1.007Intercept: 0.01Correlation: 0.9841Std. Error Est: 0.55Confidence Interval Slope: 0.958 to 1.057Confidence Interval Intercept: -0.38 to 0.40</td></tr></table>

![](images/ba68ec1e2715e70ffc359bc49ff092d206f3ad830a8ea01498af5169d9f52a2b.jpg)

#

<table><tr><td rowspan=1 colspan=8>POL - Precision for ACE and ACE Alera Clinical Chemistry Systems(Note: Refer to previously cleared submissions k1 13382, k113438 and k1 13437 for ACE AxcelPOL data)</td></tr><tr><td rowspan=2 colspan=2>Y-GT</td><td rowspan=1 colspan=3>ACE Result</td><td rowspan=1 colspan=3>ACE Alera Result</td></tr><tr><td rowspan=2 colspan=1>Mean</td><td rowspan=1 colspan=2>U/L SD, %CV</td><td rowspan=2 colspan=1>Mean</td><td rowspan=1 colspan=2>U/L SD, %CV</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>19</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.7</td><td rowspan=2 colspan=1>19</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>4.6%</td><td rowspan=1 colspan=1>9.2%</td><td rowspan=1 colspan=1>7.1%</td><td rowspan=1 colspan=1>7.9%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>17</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.7</td><td rowspan=2 colspan=1>18</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.9</td></tr><tr><td rowspan=1 colspan=1>6.4%</td><td rowspan=1 colspan=1>9.8%</td><td rowspan=1 colspan=1>4.2%</td><td rowspan=1 colspan=1>5.2%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>15</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.0</td><td rowspan=2 colspan=1>18</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.0</td></tr><tr><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>6.8%</td><td rowspan=1 colspan=1>4.8%</td><td rowspan=1 colspan=1>5.6%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>16</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.0</td><td rowspan=2 colspan=1>18</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.0</td></tr><tr><td rowspan=1 colspan=1>4.9%</td><td rowspan=1 colspan=1>6.2%</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>5.3%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>297</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>2.0</td><td rowspan=2 colspan=1>298</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>3.7</td></tr><tr><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>1.2%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>286</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>3.3</td><td rowspan=2 colspan=1>287</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>0.9%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>284</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>2.9</td><td rowspan=2 colspan=1>315</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.7%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>287</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>4.1</td><td rowspan=2 colspan=1>299</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>2.8</td></tr><tr><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>1.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>523</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>5.9</td><td rowspan=2 colspan=1>524</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>3.3</td></tr><tr><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>0.6%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>502</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>4.0</td><td rowspan=2 colspan=1>503</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>4.5</td></tr><tr><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>0.9%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>500</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>5.6</td><td rowspan=2 colspan=1>561</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>3.5</td></tr><tr><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.6%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>496</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>6.3</td><td rowspan=2 colspan=1>528</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>4.6</td></tr><tr><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.9%</td></tr></table>

Data:

Precision - POL

<table><tr><td rowspan=2 colspan=2>Lipase  </td><td rowspan=1 colspan=3>ACE Result</td><td rowspan=1 colspan=3>       ACE Alera Result</td></tr><tr><td rowspan=2 colspan=1>Mean</td><td rowspan=1 colspan=2>U/L SD, %CV</td><td rowspan=2 colspan=1>Mean</td><td rowspan=1 colspan=2>U/L SD, %CV</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>ln-House</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>23</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>. 2.5</td><td rowspan=2 colspan=1>24</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>8.2%</td><td rowspan=1 colspan=1>10.9%</td><td rowspan=1 colspan=1>8.7%</td><td rowspan=1 colspan=1>8.7%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>24</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>3.1</td><td rowspan=2 colspan=1>23</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=1 colspan=1>9.4%</td><td rowspan=1 colspan=1>12.8%</td><td rowspan=1 colspan=1>9.6%</td><td rowspan=1 colspan=1>12.0%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>21</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.4</td><td rowspan=2 colspan=1>21</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>6.8%</td><td rowspan=1 colspan=1>8.5%</td><td rowspan=1 colspan=1>8.9%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>24</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.0</td><td rowspan=2 colspan=1>22</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>6.3%</td><td rowspan=1 colspan=1>8.0%</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>10.5%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>161</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>4.2</td><td rowspan=2 colspan=1>158</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>1.9%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>167</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>6.8</td><td rowspan=2 colspan=1>154</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>7.7</td></tr><tr><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>5.0%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>134</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>5.4</td><td rowspan=2 colspan=1>154</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>3.9</td></tr><tr><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>2.5%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>152</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>5.5</td><td rowspan=2 colspan=1>148</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>3.5%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>&#x27; , &#x27;</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>321</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>7.6</td><td rowspan=2 colspan=1>315</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>11.5</td></tr><tr><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>3.7%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>327</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>12.3</td><td rowspan=2 colspan=1>292</td><td rowspan=1 colspan=1>9.9</td><td rowspan=1 colspan=1>14.5</td></tr><tr><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>5.0%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>265</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>13.3</td><td rowspan=2 colspan=1>310</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>6.3</td></tr><tr><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>2.0%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>289</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>8.7</td><td rowspan=2 colspan=1>293</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>12.3</td></tr><tr><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>4.2%</td></tr></table>

Performance

Data:

Precision - POL

<table><tr><td rowspan=2 colspan=2>T4</td><td rowspan=1 colspan=3>ACE Result</td><td rowspan=1 colspan=3>ACE Alera Result</td></tr><tr><td rowspan=2 colspan=1>Mean</td><td rowspan=1 colspan=2>μg/dL SD, %CV</td><td rowspan=2 colspan=1>Mean</td><td rowspan=1 colspan=2>μg/dL SD, %CV</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>4.2</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>0.17</td><td rowspan=2 colspan=1>4.1</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>0.17</td></tr><tr><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>4.3%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>4.0</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>0.11</td><td rowspan=2 colspan=1>4.3</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>0.15</td></tr><tr><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>3.5%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>4.2</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>0.14</td><td rowspan=2 colspan=1>4.1</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>0.18</td></tr><tr><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>4.3%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>4.2</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>0.11</td><td rowspan=2 colspan=1>3.9</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>0.20</td></tr><tr><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>5.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>10.2</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>0.19</td><td rowspan=2 colspan=1>10.1</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.33</td></tr><tr><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>3.2%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>9.9</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>0.27</td><td rowspan=2 colspan=1>10.3</td><td rowspan=1 colspan=1>0.41</td><td rowspan=1 colspan=1>0.43</td></tr><tr><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>4.2%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>10.6</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>0.52</td><td rowspan=2 colspan=1>10.1</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>0.29</td></tr><tr><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>4.9%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>2.9%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>10.5</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.20</td><td rowspan=2 colspan=1>10.1</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>0.49</td></tr><tr><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>4.9%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>16.3</td><td rowspan=1 colspan=1>0.35</td><td rowspan=1 colspan=1>0.83</td><td rowspan=2 colspan=1>16.0</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>0.41</td></tr><tr><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>2.6%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>16.1</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>0.41</td><td rowspan=2 colspan=1>16.4</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>0.89</td></tr><tr><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>5.4%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>17.1</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>0.81</td><td rowspan=2 colspan=1>16.3</td><td rowspan=1 colspan=1>0.46</td><td rowspan=1 colspan=1>0.76</td></tr><tr><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>4.7%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>17.3</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>0.33</td><td rowspan=2 colspan=1>17.6</td><td rowspan=1 colspan=1>0.79</td><td rowspan=1 colspan=1>0.97</td></tr><tr><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>5.5%</td></tr></table>

Performance

Data:

Method Comparison - POL on ACE   

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Statistic</td><td rowspan=1 colspan=1>In-House (x)vS.ACE POL 1 (y)</td><td rowspan=1 colspan=1>In-House (x)VS.ACE POL 2 (y)</td><td rowspan=1 colspan=1>In-House (x)vS.ACE POL 3 (y)</td></tr><tr><td rowspan=1 colspan=1>γ-GT</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>5115 to 866y = 0.964x + 0.70.99974.20.958 to 0.971-0.7 to 2.0</td><td rowspan=1 colspan=1>5115 to 866y = 0.976x - 2.70.99984.20.970 to 0.982-4.0 to -1.3</td><td rowspan=1 colspan=1>5115 to 866y = 0.971 x - 0.80.99992.60.967 to 0.975-1.6 to 0.1</td></tr><tr><td rowspan=1 colspan=1>Lipase</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.Cl SlopeCI Intercept</td><td rowspan=1 colspan=1>5415 to 644y = 1.002x + 0.00.99869.60.988 to 1.017-3.1 to 3.1</td><td rowspan=1 colspan=1>5115 to 676y = 0.994x - 5.30.996611.60.970 to 1.017-9.1 to -1.5</td><td rowspan=1 colspan=1>5115 to 676y = 1.03 1 x - 2.30.99877.51.016 to 1.047-4.8 to 0.2</td></tr><tr><td rowspan=1 colspan=1>T4</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>501.5 to 18.6y = 1.010x - 0.040.99360.270.977 to 1.043-0.29 to 0.22</td><td rowspan=1 colspan=1>501.5 to 18.6y = 1.019x - 0.070.99080.330.979 to 1.059-0.38 to 0.24</td><td rowspan=1 colspan=1>501.5 to 18.6y = 1.017x - 0.090.99210.310.980 to 1.054-0.38 to 0.19</td></tr></table>

![](images/4fe6004c2e1568d244d56f5caaba5a1356467d01c003d2c3c684edd295e8c8a2.jpg)

Performance

Data:

Method Comparison - POL on ACE Alera   

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Statistic</td><td rowspan=1 colspan=1>In-House (x)VS.ACE Alera POL 1(y)</td><td rowspan=1 colspan=1>In-House (x)vS.ACE Alera POL 2(y)</td><td rowspan=1 colspan=1>In-House (x)vs.ACE Alera POL 3(y)</td></tr><tr><td rowspan=1 colspan=1>γ-GT</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>5115 to 866y = 0.950x + 1.90.99983.70.945 to 0.9560.7 to 3.1</td><td rowspan=1 colspan=1>5115 to 866y = 1.028x + 2.90.99965.41.020 to 1.0361.2 to 4.7</td><td rowspan=1 colspan=1>5115 to 866y = 0.996x + 2.4.0.99974.60.990 to 1.0030.9 to 3.9</td></tr><tr><td rowspan=1 colspan=1>ipase</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>5115 to 676y = 1.028x + 3.30.996013.11.001 to 1.054-1.0 to 7.6</td><td rowspan=1 colspan=1>5015 to 676y= 1.017x -3.50.996911.40.993 to 1.040-7.3 to 0.3</td><td rowspan=1 colspan=1>5115 to 676y = 0.992x - 2.90.99886.90.978 to 1.006-5.2 to -0.7</td></tr><tr><td rowspan=1 colspan=1>T4</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>501.5 to 18.6y = 1.022x -0.140.99260.300.986 to 1.058-0.42 to 0.13</td><td rowspan=1 colspan=1>501.5 to 18.6y= 1.048x -0.310.99090.341.007 to 1.089-0.63 to 0.01</td><td rowspan=1 colspan=1>481.5 to 18.6y = 1.033x-0.100.98680.360.983 to 1.083-0.47 to 0.27</td></tr></table>

![](images/ddcbe08734fb30d8e17ee6df50f709c5442865d75d9e5e15f3a63bd32ec884c3.jpg)

Performance Data:

ACE Alera

# Performance data for the Alfa Wassermann ACE Reagents on the Alfa Wassermann ACE Alera Clinical Chemistry System

Detection Limits - ACE Alera Clinical Chemistry System

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>γ-GT</td><td rowspan=1 colspan=1>Lipase</td><td rowspan=1 colspan=1>T4</td></tr><tr><td rowspan=1 colspan=1>LOB</td><td rowspan=1 colspan=1>Original Data</td><td rowspan=1 colspan=1>3 U/L</td><td rowspan=1 colspan=1>7 U/L</td><td rowspan=1 colspan=1>0.3 μg/dL</td></tr><tr><td rowspan=1 colspan=1>LOD</td><td rowspan=1 colspan=1>Original Data</td><td rowspan=1 colspan=1>5 U/L</td><td rowspan=1 colspan=1>11 U/L</td><td rowspan=1 colspan=1>0.8 μg/dL</td></tr><tr><td rowspan=1 colspan=1>LOQ</td><td rowspan=1 colspan=1>2012 Data</td><td rowspan=1 colspan=1>7 U/L</td><td rowspan=1 colspan=1>13 U/L</td><td rowspan=1 colspan=1>1.3 μg/dL</td></tr></table>

# Linearity - ACE Alera Clinical Chemistry System

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Low LevelTested</td><td rowspan=1 colspan=1>High LevelTested</td><td rowspan=1 colspan=1>Linear to:</td><td rowspan=1 colspan=1>Linear Regressionequation</td></tr><tr><td rowspan=1 colspan=1>γ-GT</td><td rowspan=1 colspan=1>4 U/L</td><td rowspan=1 colspan=1>993 U/L</td><td rowspan=1 colspan=1>950 U/L</td><td rowspan=1 colspan=1>y = 1.036x + 0.8</td></tr><tr><td rowspan=1 colspan=1>Lipase</td><td rowspan=1 colspan=1>11 U/L</td><td rowspan=1 colspan=1>739 U/L</td><td rowspan=1 colspan=1>700 U/L</td><td rowspan=1 colspan=1>y= 0.971x + 0.2</td></tr><tr><td rowspan=1 colspan=1>T4</td><td rowspan=1 colspan=1>1.2 μg/dL</td><td rowspan=1 colspan=1>19.7 μg/dL</td><td rowspan=1 colspan=1>19.6 μg/dL</td><td rowspan=1 colspan=1>y= 1.057x-0.09</td></tr></table>

Performance Data:

ACE Alera

<table><tr><td rowspan=2 colspan=1>Interferent</td><td rowspan=1 colspan=3>No Significant Interference at or below:</td></tr><tr><td rowspan=1 colspan=1>γ-GT</td><td rowspan=1 colspan=1>Lipase</td><td rowspan=1 colspan=1>T4</td></tr><tr><td rowspan=1 colspan=1>Icterus</td><td rowspan=1 colspan=1>14.2 mg/dL</td><td rowspan=1 colspan=1>12.5 mg/dL</td><td rowspan=1 colspan=1>47.2 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemolysis</td><td rowspan=1 colspan=1>125 mg/dL</td><td rowspan=1 colspan=1>1000 mg/dL</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Lipemia</td><td rowspan=1 colspan=1>500 mg/dL</td><td rowspan=1 colspan=1>803 mg/dL</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>6 mg/dL</td><td rowspan=1 colspan=1>6 mg/dL</td><td rowspan=1 colspan=1>6 mg/dL</td></tr></table>

# Heterophile Interferences - ACE T4 on the ACE Alera Clinical Chemistry System

<table><tr><td rowspan=1 colspan=1>Heterophile</td><td rowspan=1 colspan=1>No Clinically Interfering Conditionat or below:</td></tr><tr><td rowspan=1 colspan=1>Human Anti-MouseAntibody (HAMA)</td><td rowspan=1 colspan=1>800 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor</td><td rowspan=1 colspan=1>516 IU/mL</td></tr></table>

# Cross-Reactivity - ACE T4 on the ACE Alera Clinical Chemistry System

<table><tr><td rowspan=1 colspan=1>Cross-Reactant</td><td rowspan=1 colspan=1>ConcentrationTested (μg/dL)</td><td rowspan=1 colspan=1>% Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>3,3&#x27;,5,5&#x27;-Tetraiodothyroacetic Acid</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>18.4</td></tr><tr><td rowspan=1 colspan=1>L-Thyroxine</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>91.6</td></tr><tr><td rowspan=1 colspan=1>D-Thyroxine</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>68.0</td></tr></table>

Performance Data:

ACE Alera

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Precision (SD, %CV)</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>γ-GTU/L</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>1.0, 3.4%</td><td rowspan=1 colspan=1>1.3, 4.7%</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>1.4, 2.0%</td><td rowspan=1 colspan=1>2.4, 3.4%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>1.9, 1.8%</td><td rowspan=1 colspan=1>3.6, 3.4%</td></tr><tr><td rowspan=3 colspan=1>LipaseU/L</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>6.2, 9.8%</td><td rowspan=1 colspan=1>6.2, 9.9%</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>379</td><td rowspan=1 colspan=1>10.5, 2.8%</td><td rowspan=1 colspan=1>15.4, 4.1%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>657</td><td rowspan=1 colspan=1>20.4, 3.1%</td><td rowspan=1 colspan=1>24.4, 3.7%</td></tr><tr><td rowspan=3 colspan=1>T4μg/dL</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>0.19, 3.1%</td><td rowspan=1 colspan=1>0.34, 5.6%</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>10.6</td><td rowspan=1 colspan=1>0.26, 2.4%</td><td rowspan=1 colspan=1>0.37, 3.5%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>17.1</td><td rowspan=1 colspan=1>0.56, 3.3%</td><td rowspan=1 colspan=1>0.66, 3.9%</td></tr></table>

# Method Comparison - ACE Alera Clinical Chemistry System

In-House ACE $\mathbf { \rho } ( \mathbf { x } )$ vs. In-House ACE Alera (y)   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>γ-GT</td><td rowspan=1 colspan=1>Lipase</td><td rowspan=1 colspan=1>T4</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>15 to 866 U/L</td><td rowspan=1 colspan=1>15 to 676 U/L</td><td rowspan=1 colspan=1>1.5 to 18.6μg/dL</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.975</td><td rowspan=1 colspan=1>1.038</td><td rowspan=1 colspan=1>1.004</td></tr><tr><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>-4.8</td><td rowspan=1 colspan=1>-0.08</td></tr><tr><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>0.9999</td><td rowspan=1 colspan=1>0.9995</td><td rowspan=1 colspan=1>0.9937</td></tr><tr><td rowspan=1 colspan=1>Std. Error</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>0.27</td></tr><tr><td rowspan=1 colspan=1>CI Slope</td><td rowspan=1 colspan=1>0.972 to 0.979 1.029 to 1.048</td><td rowspan=1 colspan=1>0.972 to 0.979 1.029 to 1.048</td><td rowspan=1 colspan=1>0.972 to 1.037</td></tr><tr><td rowspan=1 colspan=1>CI Intercept</td><td rowspan=1 colspan=1>3.5 to 5.2</td><td rowspan=1 colspan=1>-6.4 to -3.3</td><td rowspan=1 colspan=1>-0.33 to 0.17</td></tr></table>

<table><tr><td>Conclusions:</td><td>Based on the foregoing data, the device is safe and effective for use in clinical laboratories and physician office laboratories. These data indicate substantial equivalence for lithium heparin plasma sample collection tubes to the predicate device&#x27;s use of serum sample collection tubes. These data also indicate that the ACE Alera Clinical Chemistry System is substantially equivalent to the predicate device ACE Clinical Chemistry System.</td></tr></table>

# August 14, 2013

Alfa Wassermann Diagnostic Technologies, LLC C/O Hyman Katz, Ph.D.   
4 Henderson Drive   
WEST CALDWELL NJ 07006

Re: K131515 Trade/Device Name: ACE T4 Reagent ACE Lipase Reagent ACE $\gamma$ GT Reagent Regulation Number: 21 CFR 862.1700 Regulation Name: Total thyroxine test system Regulatory Class: II Product Code: KLI, CHI, JPZ Dated: May 24, 2013 Received: May 28, 2013

Dear Dr. Katz:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the devicc is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have bcen reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of thc Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 ); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to htp://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucml 15809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http:/www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourccsforYou/Industry/default.htm.

Sincerely yours,

# Carol C. Benson -S for

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known):_k131515

Device Name: ACE γ-GT Reagent

Indications for Use:

The ACE y-GT Rcagent is intended for the quantitative determination of gamma-glutamyltransferase activity in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Gamma-glutamyltransferase measurements are used in the diagnosis and treatment of liver discases such as alcoholic cirrhosis and primary and secondary liver tumors. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only.

# Device Name: ACE Lipase Reagent

Indications for Use: The ACE Lipase Reagent is intended for the quantitative determination of lipase activity in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Lipase measurements are used in diagnosis and treatment of diseases of the pancreas such as acule pancreatitis and obstruction of the pancreatic duct. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only.

# Page 2 of 2

# Indications for Use

510(k) Number (if known): k 131515

# Device Name: ACE T4 Reagent

# Indications for Use:

The ACE T4 Reagent is intended for the quantitative determination of total thyroxine (T4) in serum and lithium heparin plasma using the ACE, ACE Alera, and ACE Axcel Clinical Chemistry Systems. Total thyroxine measurements are used in the diagnosis and treatment of thyroid diseases. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only.

# Concurrence of CDRH, Office of In Vitro Devices or Radiological Health (OIR)

# Ruth A. Chesler -S